プロバイオティクスの保護と精密配送のための次世代マイクロエンカプスレーション技術
Yixin Zhu1, Longxian Lv2, Bingbing Du1
1Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, China.
Microbial biotechnology
|February 18, 2026
まとめ
マイクロエンカプスレーションは,経口投与中に有益なプロバイオティクスを保護し,その生存率と治療効果を高めます. このレビューでは,プロバイオティクスの安定性を向上させ,標的を絞った投与のための高度な技術を探索しています.
科学分野:
- 微生物学 微生物学とは
- バイオテクノロジー バイオテクノロジー
- マテリアルサイエンス 材料科学
背景:
- プロバイオティクスは健康に有益ですが,経口出産の生存率に問題があります.
- 胃酸,胆塩,腸の状態は,プロバイオティクスの生存能力を低下させる.
- マイクロエンカプスレーションは,プロバイオティクスを保護するための解決策を提供します.
研究 の 目的:
- プロバイオティクスのための高度なマイクロエンカプスレーション材料と技術を見直す.
- プロバイオティクスの安定性と標的の投与を強化するための戦略を検証する.
- 産業用アプリケーションの安全性とスケーラビリティを評価する.
主な方法:
- マイクロエンカプスレーション技術に関する包括的な文献レビュー.
- プロバイオティクスの保護のための材料と技術の分析.
- pH反応性および炎症を標的とするマイクロカプセルなどの高度な配送システムの評価.
主要な成果:
- 最先端の材料と技術は,プロバイオティクスの安定性を大幅に改善します.
- 先進的な配達システムは,精密な腸内放出とコロニー化を保証します.
- セキュリティとスケーラビリティの課題については,さらなる調査が必要です.
結論:
- 次世代のマイクロエンカプスレーションは,より安全で効果的なプロバイオティクスの治療を約束しています.
- 生物互換性のある材料と費用対効果の高い生産は,スケーラビリティに不可欠です.
- パーソナライズされたプロバイオティクスの治療は,高度な配送システムによって可能になります.
関連する概念動画
Microorganisms in Medicine and Therapeutics
1.2K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.2K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
230
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
230
Modified-Release Drug Delivery Systems: Site-Targeted
29
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
29
Modified-Release Drug Delivery Systems: Overview
24
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
24
Site-Targeted Drug Delivery Systems: Polymeric Carriers
31
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
31
Oral Drug Delivery Systems: Delayed-Release Systems
41
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
41


